down arrow

Talaris Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US87410C1045
USD
47.98
0.00 (0.00%)

Oct 29

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

11.5648.27
Valuation
Technical
Day's Volume

CASH

0

Shareholding (Mar 2025)

FII

7.86%

Held by 51 FIIs

DII

49.36%

Held by 21 DIIs

Promoter

24.72%

How big is Talaris Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Talaris Therapeutics, Inc. has a market capitalization of 466.18 million, with net sales of 0.00 million and a net profit of -82.87 million over the latest four quarters. The company reported shareholder's funds of 300.05 million and total assets of 309.00 million as of Dec 24.

Market Cap: <BR>As of Jun 18, Talaris Therapeutics, Inc. has a market capitalization of 466.18 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: <BR>For the latest four quarters, Talaris Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -82.87 million.<BR><BR>Balance Sheet Snapshot: <BR>As of Dec 24, the company reported shareholder's funds of 300.05 million and total assets of 309.00 million.

Read More

What does Talaris Therapeutics, Inc. do?

22-Jun-2025

Talaris Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $23 million and a market cap of $466.18 million. Key financial metrics include a negative P/E ratio, a debt equity ratio of -0.89, and a return on equity of -29.61%.

Overview: <BR>Talaris Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -23 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 466.18 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.89 <BR>Return on Equity: -29.61% <BR>Price to Book: 1.67 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Talaris Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 11, 2025, Talaris Therapeutics, Inc. has a bullish trend supported by positive MACD, Bollinger Bands, and moving averages, despite bearish RSI signals, while outperforming the S&P 500 with a 115.11% return over the past month and 135.16% year-to-date.

As of 11 August 2025, the technical trend for Talaris Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish, driven by a bullish MACD on both weekly and monthly time frames, bullish Bollinger Bands, and bullish moving averages on the daily chart. However, the RSI indicates bearish momentum on both weekly and monthly periods, suggesting some caution. The Dow Theory and OBV are both mildly bullish on the weekly and monthly time frames.<BR><BR>In terms of performance, Talaris has significantly outperformed the S&P 500 over the past month with a return of 115.11% compared to the S&P's 2.33%, and also shows strong year-to-date performance at 135.16% versus 12.22% for the S&P 500.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 603 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.92

stock-summary
Return on Equity

-34.13%

stock-summary
Price to Book

2.33

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-23 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
111.46%
0%
111.46%
6 Months
195.17%
0%
195.17%
1 Year
77.05%
0%
77.05%
2 Years
242.71%
0%
242.71%
3 Years
2917.61%
0%
2917.61%
4 Years
-71.59%
0%
-71.59%
5 Years
0%
0%
0.0%

Talaris Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Talaris Therapeutics, Inc. technically bullish or bearish?

As of 11 August 2025, the technical trend for Talaris Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish, driven by a bullish MACD on both weekly and monthly time frames, bullish Bollinger Bands, and bullish moving averages on the daily chart. However, the RSI indicates bearish momentum on both weekly and monthly periods, suggesting some caution. The Dow Theory and OBV are both mildly bullish on the weekly and monthly time frames. In terms of performance, Talaris has significantly outperformed the S&P 500 over the past month with a return of 115.11% compared to the S&P's 2.33%, and also shows strong year-to-date performance at 135.16% versus 12.22% for the S&P 500....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-202.43%
EBIT to Interest (avg)
-67.28
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.89
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.77
EV to EBIT
-2.49
EV to EBITDA
-2.49
EV to Capital Employed
7.97
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-320.12%
ROE (Latest)
-29.61%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
Bearish
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Bearish
Bearish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 28 Schemes (18.07%)

Foreign Institutions

Held by 51 Foreign Institutions (7.86%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -32.00% vs -19.05% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-26.00",
          "val2": "-22.00",
          "chgp": "-18.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-23.10",
          "val2": "-17.50",
          "chgp": "-32.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -73.87% vs -113.71% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-89.70",
          "val2": "-45.40",
          "chgp": "-97.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-73.20",
          "val2": "-42.10",
          "chgp": "-73.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-26.00
-22.00
-18.18%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-23.10
-17.50
-32.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -32.00% vs -19.05% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-89.70
-45.40
-97.58%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-73.20
-42.10
-73.87%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -73.87% vs -113.71% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Talaris Therapeutics, Inc. stock-summary
stock-summary
Talaris Therapeutics, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."